Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies

Basit Öğe Kaydı
dc.authoridVelasco, Guillermo/0000-0002-1994-2386
dc.authoridCordani, Marco/0000-0001-9342-4862
dc.authoridAlcon Rodriguez, Sergio/0000-0002-7738-567X
dc.authoridSainz, Rosa M./0000-0003-3048-5582
dc.authorwosidVelasco, Guillermo/H-5260-2012
dc.authorwosidCordani, Marco/ABF-4669-2021
dc.authorwosidSainz, Rosa M./N-5885-2014
dc.contributor.authorAmbrosini, Giulia
dc.contributor.authorCordani, Marco
dc.contributor.authorZarrabi, Ali
dc.contributor.authorAlcon-Rodriguez, Sergio
dc.contributor.authorSainz, Rosa M.
dc.contributor.authorVelasco, Guillermo
dc.contributor.authorGonzalez-Menendez, Pedro
dc.date.accessioned2024-05-19T14:46:20Z
dc.date.available2024-05-19T14:46:20Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractProstate cancer, as one of the most prevalent malignancies in males, exhibits an approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events and mutations, including the accumulation of oncometabolites, underpin the genesis and progression of this cancer type. Despite growing research demonstrating the pivotal role of oncometabolites in supporting various cancers, including prostate cancer, the root causes of their accumulation, especially in the absence of enzymatic mutations, remain elusive. Consequently, identifying a tangible therapeutic target poses a formidable challenge. In this review, we aim to delve deeper into the implications of oncometabolite accumulation in prostate cancer. We center our focus on the consequential epigenetic alterations and impacts on cancer stem cells, with the ultimate goal of outlining novel therapeutic strategies.en_US
dc.description.sponsorshipFondazione Umberto Veronesien_US
dc.description.sponsorshipNot applicable.en_US
dc.identifier.doi10.1186/s12964-023-01462-0
dc.identifier.issn1478-811X
dc.identifier.issue1en_US
dc.identifier.pmid38216942en_US
dc.identifier.scopus2-s2.0-85182238081en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1186/s12964-023-01462-0
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5497
dc.identifier.volume22en_US
dc.identifier.wosWOS:001142822200005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofCell Communication and Signalingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectProstate Canceren_US
dc.subjectOncometabolitesen_US
dc.subjectEpigenetic Alterationsen_US
dc.subjectCancer Stem Cells (Cscs)en_US
dc.subjectMetabolic Enzymesen_US
dc.subjectEmten_US
dc.titleTranscending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategiesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu